| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
AJS-2 Targeting Wnt/β-catenin signaling: E7386, an orally active selective inhibitor of the interaction between β-catenin and CREB-binding protein (CBP)
|
Adachi, Y.
|
|
|
35 |
S3 |
p. S1275
|
artikel
|
| 2 |
APJS-4 JSMO-Rising Stars in Asia Workshop – initiatives for cultivating young Asian leaders and international exchange
|
Sudo, K.
|
|
|
35 |
S3 |
p. S1276
|
artikel
|
| 3 |
CP6-2 Activities and networking of women's oncologist in ASCO and US
|
Schuchter, L.M.
|
|
|
35 |
S3 |
p. S1308
|
artikel
|
| 4 |
CP8-2 All in one cancer center and multi-disciplinary conference
|
Nakamura, M.
|
|
|
35 |
S3 |
p. S1308
|
artikel
|
| 5 |
CP4-2 Development of oncology fellowship between KSMO and KCSG in Korea: current status of oncology education and framework for future oncology of KSMO
|
Park, Y.
|
|
|
35 |
S3 |
p. S1307
|
artikel
|
| 6 |
CP2-2 Develop your online presence and foster connections: tips for using social media as a medical oncologist
|
Uehara, Y.
|
|
|
35 |
S3 |
p. S1309
|
artikel
|
| 7 |
CP4-4 Oncology education initiatives at Taiwan Oncology Society (TOS)
|
Hsu, C.
|
|
|
35 |
S3 |
p. S1307-S1308
|
artikel
|
| 8 |
CP1-2 Questionnaire on compliance with Febrile Neutropenia (FN) Guidelines 2nd ed. and risk-based patient selection for outpatient treatment in the 3rd ed.
|
Akiyama, N.
|
|
|
35 |
S3 |
p. S1307
|
artikel
|
| 9 |
CP1-3 Should we decide to screen the CMV reactivation when febrile neutropenia persisted? (JSMO FN Guideline 3rd edition, CQ11)
|
Abe, M.
|
|
|
35 |
S3 |
p. S1307
|
artikel
|
| 10 |
Disclaimer
|
|
|
|
35 |
S3 |
p. iv
|
artikel
|
| 11 |
Editorial Board
|
|
|
|
35 |
S3 |
p. ii
|
artikel
|
| 12 |
EJS-2 Assessing the value of new cancer drugs for regulatory and HTA decisions – the role of ESMO-MCBS
|
Gyawali, B.
|
|
|
35 |
S3 |
p. S1277
|
artikel
|
| 13 |
EJS-4 Dose-optimization studies of modern oncology drugs for reduction of toxicity and cost
|
Kunitoh, H.
|
|
|
35 |
S3 |
p. S1277
|
artikel
|
| 14 |
EJS-1 Economic issues for health care: patients', doctors' and payers' perspectives
|
Blay, J.
|
|
|
35 |
S3 |
p. S1277
|
artikel
|
| 15 |
EL24 Bone and soft tissue sarcoma
|
Oyama, Y.
|
|
|
35 |
S3 |
p. S1306
|
artikel
|
| 16 |
EL14 Chemotherapy for colorectal cancer and small bowel cancer
|
Takashima, A.
|
|
|
35 |
S3 |
p. S1305
|
artikel
|
| 17 |
EL19 Drug therapy in early-stage breast cancer
|
Hara, F.
|
|
|
35 |
S3 |
p. S1306
|
artikel
|
| 18 |
EL5 Immune checkpoint inhibitors
|
Kitano, S.
|
|
|
35 |
S3 |
p. S1305
|
artikel
|
| 19 |
EL2 Impact of gut microbiome on cancer immunity
|
Yoshimura, K.
|
|
|
35 |
S3 |
p. S1305
|
artikel
|
| 20 |
EL6 Supportive care in cancer and adverse event management
|
Naito, T.
|
|
|
35 |
S3 |
p. S1305
|
artikel
|
| 21 |
JS2-6 An investigator-initiated clinical trial aimed at improving outcomes of lung cancer immunotherapy
|
Tanaka, K.
|
|
|
35 |
S3 |
p. S1280
|
artikel
|
| 22 |
JS6-1 Cancer precision medicine and multi-gene panel testing (MGPT) overview
|
Hirasawa, A.
|
|
|
35 |
S3 |
p. S1283
|
artikel
|
| 23 |
JS3-2 Evidence gaps in cardio-oncology clinical practice guidelines – a sea of opportunity
|
Sase, K.
|
|
|
35 |
S3 |
p. S1281
|
artikel
|
| 24 |
JS1-2 From cancer survivorship perspective in medical oncology
|
Sasaki, J.
|
|
|
35 |
S3 |
p. S1284
|
artikel
|
| 25 |
JS4-5 Impairments, disabilities, and handicaps in cancer patients with bone metastases
|
Kido, A.
|
|
|
35 |
S3 |
p. S1282
|
artikel
|
| 26 |
JS7-5 Pharmacotherapy for bone metastasis pain
|
Matsuoka, H.
|
|
|
35 |
S3 |
p. S1279
|
artikel
|
| 27 |
JS2-3 The present & prospective of precision oncology in solid tumors – unraveling from SCRUM & CIRCULATE-Japan
|
Yoshino, T.
|
|
|
35 |
S3 |
p. S1280
|
artikel
|
| 28 |
ME15 Antibody-drug conjugate and novel therapy in lung cancer
|
Cho, B.
|
|
|
35 |
S3 |
p. S1310-S1311
|
artikel
|
| 29 |
ME8 Cancer survivorship care: how can we contribute to survivors who live beyond treatment?
|
Takahashi, M.
|
|
|
35 |
S3 |
p. S1310
|
artikel
|
| 30 |
ME2 Current insights of chemotherapy in colorectal cancer
|
Tabernero, J.
|
|
|
35 |
S3 |
p. S1310
|
artikel
|
| 31 |
ME14 Immunotherapy for gastroesophageal cancer: a 2024 update
|
Lorenzen, S.
|
|
|
35 |
S3 |
p. S1310
|
artikel
|
| 32 |
MO15-5 A comparison of the efficacy and safety of CapeOX and DS as adjuvant chemotherapy for pStage III gastric cancer
|
Imai, T.
|
|
|
35 |
S3 |
p. S1335
|
artikel
|
| 33 |
MO23-4 A feasibility study to evaluate clinical utility of stress data collection in cancer patients treated with chemotherapy
|
Doi, A.
|
|
|
35 |
S3 |
p. S1339
|
artikel
|
| 34 |
MO60-3 Aggregated analysis of integrated whole exome (WES) and whole transcriptome (WTS) sequencing in 1,000 cancer patients
|
Chernyshov, K.
|
|
|
35 |
S3 |
p. S1360
|
artikel
|
| 35 |
MO59-1 An investigator-initiated phase II trial of tirabrutinib in patients with relapsed or refractory secondary CNS lymphoma
|
Munakata, W.
|
|
|
35 |
S3 |
p. S1360
|
artikel
|
| 36 |
MO35-3 A phase II study of weekly carboplatin and concurrent radiotherapy for locally advanced NSCLC in elderly patients
|
Harada, T.
|
|
|
35 |
S3 |
p. S1345
|
artikel
|
| 37 |
MO42-5 A phase 2 study of intrapatient dose escalation of bi-weekly FTD/TPI plus BEV for colorectal cancer (E-BiTS study)
|
Wakabayashi, M.
|
|
|
35 |
S3 |
p. S1350
|
artikel
|
| 38 |
MO49-5 Appropriate SDM and ACP are required during chemotherapy for advanced stage cancer; concerns seen in the SAE database
|
Tsujimura, H.
|
|
|
35 |
S3 |
p. S1354-S1355
|
artikel
|
| 39 |
MO23-5 A retrospective study of the management of distal lower extremity deep vein thrombosis in patients with cancer
|
Okumura, H.
|
|
|
35 |
S3 |
p. S1339
|
artikel
|
| 40 |
MO50-1 A review of comprehensive genomic profiling of cholangiocarcinoma in Japan
|
Tange, E.
|
|
|
35 |
S3 |
p. S1355
|
artikel
|
| 41 |
MO7-5 Artificial intelligence-assisted colonoscopy detection rate on colorectal neoplasia patient: a systematic review of RCTs
|
Sabran, M.Z.
|
|
|
35 |
S3 |
p. S1331-S1332
|
artikel
|
| 42 |
MO7-4 Artificial neural network application in NSCLC overall staging prediction
|
Cheung, E.Y.W.
|
|
|
35 |
S3 |
p. S1331
|
artikel
|
| 43 |
MO44-1 Assessing PSA decline kinetics and Kelim as predictors of survival in docetaxel-treated prostate cancer patients
|
Hata, S.
|
|
|
35 |
S3 |
p. S1351
|
artikel
|
| 44 |
MO32-1 Assessing the impact of comprehensive genome profiling in clinical practice: single-center observational study in Japan
|
Sugimoto, N.
|
|
|
35 |
S3 |
p. S1343-S1344
|
artikel
|
| 45 |
MO61-5 Associations between plasma levels of C-reactive protein and venetoclax in patients with acute myeloid leukemia
|
Kobayashi, M.
|
|
|
35 |
S3 |
p. S1361
|
artikel
|
| 46 |
MO48-2 Cardiotoxicity after high cumulative dose of anthracyclines in adults with advanced soft tissue sarcomas: a meta-analysis
|
Franco, P.G.
|
|
|
35 |
S3 |
p. S1354
|
artikel
|
| 47 |
MO50-6 Characterization of patients with advanced biliary tract cancer by KRAS alteration subtypes
|
Shibuki, T.
|
|
|
35 |
S3 |
p. S1356
|
artikel
|
| 48 |
MO41-6 Chemotherapy for metastatic or recurrent soft tissue sarcoma: real-world experience in a single institute
|
Maeda, O.
|
|
|
35 |
S3 |
p. S1349
|
artikel
|
| 49 |
MO4-1 Clinical outcome of peptide receptor radionuclide therapy for patients with advanced neuroendocrine tumor
|
Shibuki, T.
|
|
|
35 |
S3 |
p. S1329-S1330
|
artikel
|
| 50 |
MO19-2 Clinical outcome of treatment rechallenge with HER2-directed antibody-drug conjugate in metastatic breast cancer
|
Ando, M.M.
|
|
|
35 |
S3 |
p. S1336
|
artikel
|
| 51 |
MO63-2 Clinical practice of oncotype DX in our institute: a comparative analysis of cases before and after approval
|
Mamori, T.
|
|
|
35 |
S3 |
p. S1362-S1363
|
artikel
|
| 52 |
MO39-1 Clinical utility of cancer gene panel testing from real-world data: focusing on discrepancies between CDx and CGP
|
Okugawa, Y.
|
|
|
35 |
S3 |
p. S1347-S1348
|
artikel
|
| 53 |
MO5-4 Clinical utility of upfront comprehensive genomic profiling for the treatment of advanced pancreatic cancer
|
So, E.
|
|
|
35 |
S3 |
p. S1331
|
artikel
|
| 54 |
MO38-2 Clinicopathological features of early-onset colorectal cancer
|
Okagawa, Y.
|
|
|
35 |
S3 |
p. S1346-S1347
|
artikel
|
| 55 |
MO32-2 Comparison based on the CGP test results between the early and the late period for access to treatments
|
Yamazaki, M.
|
|
|
35 |
S3 |
p. S1344
|
artikel
|
| 56 |
MO19-3 Comparison of HER2 expression status between conventional HER2 test and VENTANA HER2 (4B5) of metastatic breast cancer
|
Tokudome, N.
|
|
|
35 |
S3 |
p. S1336-S1337
|
artikel
|
| 57 |
MO46-6 Comparison of surgery, radiotherapy, chemotherapy, or in combination in histiocytic sarcoma: a systematic review
|
Tjandra, M.
|
|
|
35 |
S3 |
p. S1353
|
artikel
|
| 58 |
MO27-5 Concurrent leiomyosarcoma and diffuse astrocytoma in a Li-Fraumeni syndrome patient: a case report
|
Ito, N.
|
|
|
35 |
S3 |
p. S1342
|
artikel
|
| 59 |
MO37-3 Construction of data for implementation of comprehensive cancer genome profiling using genome-guided system
|
Sunakawa, Y.
|
|
|
35 |
S3 |
p. S1346
|
artikel
|
| 60 |
MO29-5 Correlation of COVID-19 pandemic and medical seeking behaviour in breast cancer patients at Siloam Hospitals Lippo Village
|
Sie, C. Valeria
|
|
|
35 |
S3 |
p. S1343
|
artikel
|
| 61 |
MO48-1 C-reactive protein as prognostic factor in soft tissue sarcoma: a systematic review and meta-analysis
|
Chandra, A.I.
|
|
|
35 |
S3 |
p. S1353-S1354
|
artikel
|
| 62 |
MO57-6 Definitive concurrent chemoradiotherapy in patients of synchronous esophageal and head and neck cancer in Vietnam
|
Ngoc Hoang, G.
|
|
|
35 |
S3 |
p. S1359
|
artikel
|
| 63 |
MO60-2 Detection of copy number alterations in plasma of East Asian cancer patients
|
Olsen, S.
|
|
|
35 |
S3 |
p. S1360
|
artikel
|
| 64 |
MO2-6 Does the starting dose of cabozantinib for metastatic renal cell carcinoma affect treatment efficacy/adverse events?
|
Miura, N.
|
|
|
35 |
S3 |
p. S1329
|
artikel
|
| 65 |
MO2-1 Dosimetric comparison: volumetric modulated arc therapy and stereotactic body radiotherapy for prostate cancer patients
|
Cheung, E.Y.W.
|
|
|
35 |
S3 |
p. S1328-S1329
|
artikel
|
| 66 |
MO41-3 Effectiveness and prospects of eribulin therapy for advanced sarcoma
|
Okita, Y.
|
|
|
35 |
S3 |
p. S1348-S1349
|
artikel
|
| 67 |
MO45-1 Effectiveness of short-duration on-demand training in lung cancer patient care
|
Onodera, Y.
|
|
|
35 |
S3 |
p. S1351-S1352
|
artikel
|
| 68 |
MO57-3 Effect of immunochemotherapy time-of-day infusion, sequence and interval on prognosis of advanced esophageal cancer
|
Huang, S.
|
|
|
35 |
S3 |
p. S1359
|
artikel
|
| 69 |
MO3-4 Efficacy and safety of FOLFIRINOX in comparison to gemcitabine as adjuvant therapy for PC patients: a systematic review
|
Tanially, E.
|
|
|
35 |
S3 |
p. S1329
|
artikel
|
| 70 |
MO8-3 Efficacy and safety of methadone for pain induced by bone metastasis in cancer patients
|
Nishibori, Y.
|
|
|
35 |
S3 |
p. S1332
|
artikel
|
| 71 |
MO5-1 Efficacy and safety of olaparib as a potential treatment for patients with pancreatic cancer: a systematic review
|
Charlie Chang, C.
|
|
|
35 |
S3 |
p. S1330
|
artikel
|
| 72 |
MO42-6 Efficacy and safety of tipiracil combined with bevacizumab in metastatic colon cancer patients: a systematic review
|
Glory, H.
|
|
|
35 |
S3 |
p. S1350
|
artikel
|
| 73 |
MO18-5 Efficacy and safety of veliparib with first-line chemotherapy as combination therapy in OC: a systematic review
|
Ardalin Cendera, C.
|
|
|
35 |
S3 |
p. S1335-S1336
|
artikel
|
| 74 |
MO12-6 Efficacy and safety of venetoclax and azacytidine for acute myeloid leukemia: a retrospective, single-center study
|
Yamaguchi, Y.
|
|
|
35 |
S3 |
p. S1333
|
artikel
|
| 75 |
MO26-1 Efficacy and safety of zanubrutinib in patients with relapsed or refractory mantle cell lymphoma: a systematic review
|
Febrian Santoso, A.
|
|
|
35 |
S3 |
p. S1341
|
artikel
|
| 76 |
MO62-2 Efficacy and tolerability of KEYNOTE-522 regimen for Japanese population: a single institute retrospective study
|
Aoyama, Y.
|
|
|
35 |
S3 |
p. S1362
|
artikel
|
| 77 |
MO61-1 Efficacy of DA-EPOCH-R as first-line therapy for diffuse large B-cell lymphoma: a comprehensive review and meta-analysis
|
Putra, M.R.
|
|
|
35 |
S3 |
p. S1361
|
artikel
|
| 78 |
MO61-6 Efficacy of enasidenib on acute myeloid leukemia: a systematic review
|
Fu, R.C.E.
|
|
|
35 |
S3 |
p. S1361-S1362
|
artikel
|
| 79 |
MO3-3 Efficacy of FOLFIRINOX versus G-nP for borderline resectable and locally advanced pancreatic cancer: a meta-analysis
|
Lim, Y.
|
|
|
35 |
S3 |
p. S1329
|
artikel
|
| 80 |
MO52-4 Efficacy of pembrolizumab as an adjuvant therapy vs. chemotherapy in patients with cervical cancer: a systematic review
|
Esperanza, M.
|
|
|
35 |
S3 |
p. S1357
|
artikel
|
| 81 |
MO41-5 Efficacy of pomalidomide in patients with kaposi sarcoma: a systematic review
|
Maulidia, S.A.
|
|
|
35 |
S3 |
p. S1349
|
artikel
|
| 82 |
MO4-5 Efficacy of selpercatinib as tyrosine kinase inhibitor in RET-mutant medullary thyroid cancer: a systematic review
|
Relia Margouw, R.
|
|
|
35 |
S3 |
p. S1330
|
artikel
|
| 83 |
MO15-2 Establishing real-world data on actual advanced gastric cancer therapy using CyberOncology: a feasibility study
|
Machida, N.
|
|
|
35 |
S3 |
p. S1335
|
artikel
|
| 84 |
MO25-1 Evaluation of HER2 expression across various solid tumors in Vietnamese patients: a large-scale study
|
Thanh Nguyen, L.
|
|
|
35 |
S3 |
p. S1339-S1340
|
artikel
|
| 85 |
MO50-7 Evaluation of preoperative chemotherapy and cancer genome therapy for intrahepatic cholangiocarcinoma in our hospital
|
Matsumoto, T.
|
|
|
35 |
S3 |
p. S1356
|
artikel
|
| 86 |
MO7-6 Exploring the holistic needs assessment in Integrated Cancer Care Program
|
Lin, W.
|
|
|
35 |
S3 |
p. S1332
|
artikel
|
| 87 |
MO20-4 Extranodal lesions of DLBCL at the 1st relapse might predict CNS lesions in the 2nd relapse
|
Okabe, Y.
|
|
|
35 |
S3 |
p. S1338
|
artikel
|
| 88 |
MO42-1 FOLFOXIRI-Bev as first-line treatment in patients with metastatic colorectal cancer: a systematic review of RCT
|
Luih, B. Stephanie
|
|
|
35 |
S3 |
p. S1349-S1350
|
artikel
|
| 89 |
MO36-1 Future treatment strategies for advanced thyroid cancer based on genetic mutation
|
Ito, K.
|
|
|
35 |
S3 |
p. S1345
|
artikel
|
| 90 |
MO58-6 Genetic variants in mitochondria contribute the risk of familial lung cancer
|
Yang, S.
|
|
|
35 |
S3 |
p. S1359-S1360
|
artikel
|
| 91 |
MO53-2 Harnessing artificial intelligence and big data for prognostic advancements in hormone receptor-positive breast cancer
|
Takeshita, T.
|
|
|
35 |
S3 |
p. S1358
|
artikel
|
| 92 |
MO25-6 Hypofractionated post-operative radiation in head and neck cancers (HNC): a preliminary account of locoregional control
|
Ghosh, A.
|
|
|
35 |
S3 |
p. S1341
|
artikel
|
| 93 |
MO46-2 Identification of prognostic biomarkers corresponding to relapsed/refractory multiple myeloma using a proteomic approach
|
Chantkran, W.
|
|
|
35 |
S3 |
p. S1352
|
artikel
|
| 94 |
MO40-3 Impact of acquired RAS, BRAF and PIK3CA mutation at 8 weeks on the efficacy of anti- EGFR monoclonal antibodies in mCRC
|
Kudo, T.
|
|
|
35 |
S3 |
p. S1348
|
artikel
|
| 95 |
MO32-5 Impact of patient travel costs on disparities in precision oncology clinical trials
|
Uehara, Y.
|
|
|
35 |
S3 |
p. S1344
|
artikel
|
| 96 |
MO53-6 Impact of prior anticancer therapy on tumor mutational burden in patients with metastatic breast cancer
|
Baba, K.
|
|
|
35 |
S3 |
p. S1358
|
artikel
|
| 97 |
MO41-4 Importance of local control of primary cardiac sarcomas: a report of 5 cases
|
Nishitarumizu, N.
|
|
|
35 |
S3 |
p. S1349
|
artikel
|
| 98 |
MO14-4 Improving survival outcomes with ambulatory chemotherapy in metastatic colorectal cancer in Ramathibodi Hospital
|
Chansriwong, P.
|
|
|
35 |
S3 |
p. S1334
|
artikel
|
| 99 |
MO27-2 Intramedullary spinal cord tumors (IMSCT) in paediatric population: a retrospective analysis of 45 cases
|
Gupta, S.
|
|
|
35 |
S3 |
p. S1342
|
artikel
|
| 100 |
MO22-5 Knowledge, attitudes, and practices of oncology fellows-in-training on oncofertility in breast cancer in the young
|
Sy, F.A.
|
|
|
35 |
S3 |
p. S1338
|
artikel
|
| 101 |
MO22-6 Landscape of AJCC staging system: limitations and improvements for communication with patients
|
Yoon, W.
|
|
|
35 |
S3 |
p. S1338-S1339
|
artikel
|
| 102 |
MO44-2 Leukemia inhibitory factor signaling drives immunosuppression and neuroendocrine differentiation in prostate cancer
|
Liu, Y.
|
|
|
35 |
S3 |
p. S1351
|
artikel
|
| 103 |
MO20-2 Long-term follow-up shows epcoritamab drives deep, durable responses in relapsed/refractory follicular lymphoma (R/R FL)
|
Izutsu, K.
|
|
|
35 |
S3 |
p. S1337
|
artikel
|
| 104 |
MO62-5 Neoadjuvant chemotherapy treatment triple-negative breast cancer women younger than 45 years of age
|
Dinh, A.
|
|
|
35 |
S3 |
p. S1362
|
artikel
|
| 105 |
MO47-4 Neutrophil-lymphocyte ratio predicts prognosis in bone metastasis: meta-analysis of retrospective studies
|
Gunawan, H.M.
|
|
|
35 |
S3 |
p. S1353
|
artikel
|
| 106 |
MO45-4 New initiatives for urological cancer genome outpatient services at our hospital
|
Okawa, M.
|
|
|
35 |
S3 |
p. S1352
|
artikel
|
| 107 |
MO49-1 Optimal video duration for sustaining viewership and engagement in breast cancer treatment information
|
Fushimi, A.
|
|
|
35 |
S3 |
p. S1354
|
artikel
|
| 108 |
MO24-1 Outcomes of adjuvant therapy with anti-PD-1 antibody for mucosal melanoma
|
Okumura, M.
|
|
|
35 |
S3 |
p. S1339
|
artikel
|
| 109 |
MO28-5 Outcomes of immune-related liver injury managed by hepatologists in a multidisciplinary toxicity team
|
Ito, T.
|
|
|
35 |
S3 |
p. S1342-S1343
|
artikel
|
| 110 |
MO6-1 Overall survival and safety of tebentafusp as potential treatment for patients with uveal melanoma: a systematic review
|
Santoso, K. Aurelia
|
|
|
35 |
S3 |
p. S1331
|
artikel
|
| 111 |
MO9-4 Palbociclib plus letrozole vs letrozole alone in ER+/HER2− advanced breast cancer: a systematic review and meta-analysis
|
Sabran, M.Z.
|
|
|
35 |
S3 |
p. S1332-S1333
|
artikel
|
| 112 |
MO51-2 Patient and physician preferences for systemic therapy combined with TACE for hepatocellular carcinoma
|
Furuse, J.
|
|
|
35 |
S3 |
p. S1356
|
artikel
|
| 113 |
MO25-5 Phase II study of 54 Gy accelerated hyperfractionated thoracic radiotherapy in limited-stage small-cell lung cancer
|
Kono, M.
|
|
|
35 |
S3 |
p. S1340-S1341
|
artikel
|
| 114 |
MO25-2 Phase 1 study of tusamitamab ravtansine every 2 weeks with loading dose in Japanese patients with advanced solid tumors
|
Kadowaki, S.
|
|
|
35 |
S3 |
p. S1340
|
artikel
|
| 115 |
MO60-4 Plasma ERBB2 gene alteration profiling in East Asian cancer patients
|
Olsen, S.
|
|
|
35 |
S3 |
p. S1361
|
artikel
|
| 116 |
MO62-6 Poor response to neoadjuvant chemotherapy of metaplastic breast cancer: a single institution analysis
|
Nguyen, L. Thanh
|
|
|
35 |
S3 |
p. S1362
|
artikel
|
| 117 |
MO13-1 Potential value of NLR for NIVO + IPI in MSI-H gastric cancer: sub-analysis of the NO LIMIT study (WJOG13320G/CA209-7W7)
|
Sugimoto, N.
|
|
|
35 |
S3 |
p. S1334
|
artikel
|
| 118 |
MO10-1 Pre- and post-treatment biomarkers for non-small cell lung cancer treated with immune checkpoint inhibitor
|
Murata, D.
|
|
|
35 |
S3 |
p. S1333
|
artikel
|
| 119 |
MO40-1 Predictors for m-FOLFOXIRI plus cetuximab in RAS/BRAF wild-type and left-sided mCRC: the DEEPER trial (JACCRO CC-13)
|
Natsume, S.
|
|
|
35 |
S3 |
p. S1348
|
artikel
|
| 120 |
MO10-4 Pretreatment eosinophil counts as a predictive biomarker in NSCLC patients treated with immune checkpoint inhibitors
|
Takeuchi, E.
|
|
|
35 |
S3 |
p. S1333
|
artikel
|
| 121 |
MO30-2 Prognostic impact of AKAP8 expression in breast cancer patients
|
Matsumoto, N.
|
|
|
35 |
S3 |
p. S1343
|
artikel
|
| 122 |
MO47-5 Progression free survival of larotrectinib in patients with NTRK fusion-positive tumors: a systematic review
|
MA Sumampow, M.
|
|
|
35 |
S3 |
p. S1353
|
artikel
|
| 123 |
MO18-6 Prospective changes in financial toxicity and health-related quality of life in patients with gynecologic cancer
|
Kajimoto, Y.
|
|
|
35 |
S3 |
p. S1336
|
artikel
|
| 124 |
MO19-5 Real-world and post-marketing disproportionality analysis of T-DM1: data mining of FDA adverse event reporting system
|
Chen, E.
|
|
|
35 |
S3 |
p. S1337
|
artikel
|
| 125 |
MO20-6 Real-world treatment patterns and outcomes in Japanese patients with large B-cell lymphoma after two systemic therapies
|
Liao, L.
|
|
|
35 |
S3 |
p. S1338
|
artikel
|
| 126 |
MO52-6 Results of treatment for FIGO stage I-II vulvar squamous cell carcinoma at Viet Nam National Cancer Hospital
|
Nguyen, A. Quang
|
|
|
35 |
S3 |
p. S1357
|
artikel
|
| 127 |
MO36-3 Retrospective analysis of lenvatinib use for anaplastic thyroid carcinoma management in our facility
|
Tsunoda, A.
|
|
|
35 |
S3 |
p. S1345
|
artikel
|
| 128 |
MO9-3 Ribociclib plus letrozole vs. letrozole alone in HR+/HER2− advanced breast cancer: a systematic review and meta-analysis
|
Sabran, M.Z.
|
|
|
35 |
S3 |
p. S1332
|
artikel
|
| 129 |
MO53-4 Sacituzumab Govitecan-Hziy as treatment in metastatic breast cancer: a systematic review and meta-analysis of RCTs
|
Andrina Liem, J.
|
|
|
35 |
S3 |
p. S1358
|
artikel
|
| 130 |
MO26-2 Safety and efficacy ibrutinib in mantle-cell lymphoma: a systematic review of RCTs
|
Atmaja, W. Surya
|
|
|
35 |
S3 |
p. S1341
|
artikel
|
| 131 |
MO26-6 Safety and efficacy of tis-cel compared to other CAR-T cell therapies as treatment for R/R DLBCL: a systematic review
|
Cendera, C. Ardalin
|
|
|
35 |
S3 |
p. S1341-S1342
|
artikel
|
| 132 |
MO25-3 Safety and pharmacokinetics of tusamitamab ravtansine dosing Q3W in Japanese patients with advanced solid tumors
|
Mishima, S.
|
|
|
35 |
S3 |
p. S1340
|
artikel
|
| 133 |
MO1-2 Safety profile of LIGHT-NING 3rd interim analysis: 1L nivolumab + ipilimumab +/− chemotherapy for metastatic NSCLC
|
Azuma, K.
|
|
|
35 |
S3 |
p. S1328
|
artikel
|
| 134 |
MO4-4 Short-term outcomes of nivolumab plus chemotherapy for advanced gastric neuroendocrine cell carcinoma
|
Onishi, M.
|
|
|
35 |
S3 |
p. S1330
|
artikel
|
| 135 |
MO50-3 TCOG T3221 study: the registry of genetic alterations of Taiwan biliary tract cancer
|
Chiang, N.
|
|
|
35 |
S3 |
p. S1355
|
artikel
|
| 136 |
MO46-4 The analysis of polycythemia using Yamagata city citizen health checkup data
|
Kato, Y.
|
|
|
35 |
S3 |
p. S1352-S1353
|
artikel
|
| 137 |
MO1-6 The COVID-19 pandemic and time to treatment for patients with metastatic lung adenocarcinoma in the United States
|
Iorgulescu, B.
|
|
|
35 |
S3 |
p. S1328
|
artikel
|
| 138 |
MO29-4 The effect of coronavirus 2019 (COVID-19) pandemic on breast cancer’s diagnosis, staging and treatment
|
Chong, C.
|
|
|
35 |
S3 |
p. S1343
|
artikel
|
| 139 |
MO38-1 The effects of the COVID-19 pandemic on time to treatment for stage III colonic adenocarcinoma in the United States
|
Iorgulescu, B.
|
|
|
35 |
S3 |
p. S1346
|
artikel
|
| 140 |
MO34-3 The efficacy of combined EGFR-TKI plus VEGF inhibitor/cytotoxic therapy for PD-L1-positive EGFR-mutant NSCLC: NJLCG2202
|
Kawashima, Y.
|
|
|
35 |
S3 |
p. S1344-S1345
|
artikel
|
| 141 |
MO44-4 The level of gene expression of polyamine metabolism proteins in human prostate cancer and benign prostatic hyperplasia
|
Bentrad, V.V.
|
|
|
35 |
S3 |
p. S1351
|
artikel
|
| 142 |
MO18-3 The role of exercise intervention in women with ovarian cancer undergoing chemotherapy: a systematic review
|
Rusbiyanto, M.C.
|
|
|
35 |
S3 |
p. S1335
|
artikel
|
| 143 |
MO38-6 The utility of circulating tumor DNA in gastrointestinal stromal tumor – a pooled analysis of SCRUM-Japan trials
|
Hashimoto, T.
|
|
|
35 |
S3 |
p. S1347
|
artikel
|
| 144 |
MO48-5 Third-line chemotherapy for recurrent/refractory rhabdomyosarcoma in adults: a single-center retrospective study
|
Imai, T.
|
|
|
35 |
S3 |
p. S1354
|
artikel
|
| 145 |
MO55-5 Transoral endoscopic thyroidectomy by vestibular approach in Viet Nam: surgical outcomes and mid-term follow-up
|
Xuan Nguyen, Hien.
|
|
|
35 |
S3 |
p. S1358-S1359
|
artikel
|
| 146 |
MO19-4 Trastuzumab deruxtecan, its efficacy in patients with metastatic HER2-positive breast cancer: a systematic review
|
Fernhandho, V.
|
|
|
35 |
S3 |
p. S1337
|
artikel
|
| 147 |
MO53-1 Tumour suppressor microRNAs (200a, 200b, miR205 & miR 145) and breast cancer stem cells in patients of breast carcinoma
|
Dwivedi, S.
|
|
|
35 |
S3 |
p. S1357-S1358
|
artikel
|
| 148 |
MO14-5 Umbrella reviews of systematic reviews evaluating the effects of immunonutrients on cancer patients undergoing surgery
|
Lin, W.
|
|
|
35 |
S3 |
p. S1334
|
artikel
|
| 149 |
MO43-6 UPRISE study: anxiety in patients with urothelial cancer in postoperative period -relation to patient demographics-
|
Morishima, N.
|
|
|
35 |
S3 |
p. S1350-S1351
|
artikel
|
| 150 |
MO63-6 Utility of comprehensive genomic profiling for malignant breast tumors – a single institutional experience
|
Ozaki, Y.
|
|
|
35 |
S3 |
p. S1363
|
artikel
|
| 151 |
MO63-4 Utility of IHC-based markers for predicting pathological complete response in early-stage triple-negative breast cancer
|
Funasaka, C.
|
|
|
35 |
S3 |
p. S1363
|
artikel
|
| 152 |
MO52-2 YinYang 1 (YY1) and P53 gene expression analysis in cervical cancer and its relationship with cancer staging
|
Wibisono, J.
|
|
|
35 |
S3 |
p. S1357
|
artikel
|
| 153 |
MO1-1 6y update of 1L nivolumab + ipilimumab (N+I) in metastatic (m) NSCLC, including in Japanese pts, from CheckMate 227
|
Nishio, M.
|
|
|
35 |
S3 |
p. S1327
|
artikel
|
| 154 |
O14-5 Anticoagulation for distal deep venous thrombosis in cancer patients; a post-hoc analysis from PROVE-emboli study
|
Nose, T.
|
|
|
35 |
S3 |
p. S1323
|
artikel
|
| 155 |
O7-4 A phase 1 study of zanidatamab monotherapy in Japanese patients with metastatic or unresectable HER2-expressing cancers
|
Doi, T.
|
|
|
35 |
S3 |
p. S1318-S1319
|
artikel
|
| 156 |
O10-1 A single centre experience on adolescent and young adult oncology (AYAO) patient perspectives on fertility preservation
|
Ong, Z.
|
|
|
35 |
S3 |
p. S1319-S1320
|
artikel
|
| 157 |
O10-3 Characteristics and support of cancer patients receiving financial counseling at a Cancer Counseling and Support Center
|
Kawasaki, Y.
|
|
|
35 |
S3 |
p. S1320
|
artikel
|
| 158 |
O4-4 Circulating microRNA as liquid biopsy biomarker for prediction of oncological outcomes in patients with bladder cancer
|
Urabe, F.
|
|
|
35 |
S3 |
p. S1316
|
artikel
|
| 159 |
O17-5 Clinical impact of 18F-FDG-PET/CT in predicting ICI-induced ILD in patients with lung cancer
|
Watanabe, S.
|
|
|
35 |
S3 |
p. S1325
|
artikel
|
| 160 |
O15-5 COVID-19 in patients during treatment at the outpatient chemotherapy unit
|
Kinoshita, S.
|
|
|
35 |
S3 |
p. S1323-S1324
|
artikel
|
| 161 |
O10-4 Current status and future of patient and public involvement in pancreatic cancer clinical practice guidelines revision
|
Sakamoto, Y.
|
|
|
35 |
S3 |
p. S1320
|
artikel
|
| 162 |
O15-2 Current status of distress screening among cancer patients: a survey of requirements in designated cancer care hospitals
|
Sakane, J.
|
|
|
35 |
S3 |
p. S1323
|
artikel
|
| 163 |
O9-5 Efficacy of eribulin therapy in patients with advanced adenoid cystic carcinoma receiving platinum-based chemotherapy
|
Sanomachi, T.
|
|
|
35 |
S3 |
p. S1319
|
artikel
|
| 164 |
O14-3 Efficacy of platinum-based chemotherapy in BRCA-mut advanced solid tumors: analysis using the C-CAT database
|
Ishibashi, N.
|
|
|
35 |
S3 |
p. S1322
|
artikel
|
| 165 |
O16-5 Epcoritamab in Japanese patients with relapsed/refractory diffuse large B-cell lymphoma: EPCORE NHL-3 longer-term data
|
Izutsu, K.
|
|
|
35 |
S3 |
p. S1324-S1325
|
artikel
|
| 166 |
O3-4 First-line tislelizumab plus chemotherapy in gastric/gastroesophageal junction cancer: RATIONALE-305 Asian Subgroup
|
Kato, K.
|
|
|
35 |
S3 |
p. S1316
|
artikel
|
| 167 |
O6-4 Impact of PIK3CA and cell cycle pathway alterations on durvalumab efficacy in head and neck squamous cell carcinoma
|
Kim, D.
|
|
|
35 |
S3 |
p. S1318
|
artikel
|
| 168 |
O5-3 Initiatives to improve the treatment opportunity using the patient-proposed healthcare services – the BELIEVE trial
|
Kondo, K.
|
|
|
35 |
S3 |
p. S1317
|
artikel
|
| 169 |
O15-3 Osteoporosis treatment in cancer patients: insights and challenges from specialized facilities
|
Koyanagi, H.
|
|
|
35 |
S3 |
p. S1323
|
artikel
|
| 170 |
O6-1 Post-hoc analysis of TRAEs observed in a phase 2 study of encorafenib + binimetinib in metastatic BRAF V600-mutated TC
|
Takahashi, S.
|
|
|
35 |
S3 |
p. S1317
|
artikel
|
| 171 |
O13-3 Predicting therapeutic response to PARP inhibitors in high-grade serous ovarian cancer: a comprehensive proteomics study
|
Kim, S.
|
|
|
35 |
S3 |
p. S1321
|
artikel
|
| 172 |
O16-2 Predicting the responder for pralatrexate against PTCL: a post hoc analysis of PDX-JP1 study
|
Shimazu, Y.
|
|
|
35 |
S3 |
p. S1324
|
artikel
|
| 173 |
O13-2 Raludotatug deruxtecan (R-DXd; DS-6000) in Japanese patients with ovarian cancer: subgroup analysis of a phase 1 study
|
Sudo, K.
|
|
|
35 |
S3 |
p. S1321
|
artikel
|
| 174 |
O6-2 Real-world treatment patterns of patients with locally advanced squamous cell carcinoma of the head and neck in Japan
|
Nibu, K.
|
|
|
35 |
S3 |
p. S1318
|
artikel
|
| 175 |
O18-5 Sacituzumab govitecan in Japanese patients with metastatic triple-negative breast cancer: phase 2 results of ASCENT J02
|
Naito, Y.
|
|
|
35 |
S3 |
p. S1326
|
artikel
|
| 176 |
O12-1 Safety of a short-term infusion of fosnetupitant in patients with gastrointestinal and breast cancer
|
Hashimoto, N.
|
|
|
35 |
S3 |
p. S1320
|
artikel
|
| 177 |
O18-2 Second interim analysis of REIWA study (JBCRG-C07), observational study of gene panel testing in metastatic breast cancer
|
Tada, H.
|
|
|
35 |
S3 |
p. S1325
|
artikel
|
| 178 |
O16-3 The impact of geriatric nutrition risk index on prognosis in patients with DLBCL
|
Lee, S.
|
|
|
35 |
S3 |
p. S1324
|
artikel
|
| 179 |
O9-3 Time to surgery and radioiodine for patients with high-risk thyroid carcinoma during the COVID-19 pandemic in the U.S.
|
Castellanos, L.
|
|
|
35 |
S3 |
p. S1319
|
artikel
|
| 180 |
O14-2 Updated tumor agnostic efficacy of selpercatinib in patients with RET fusion-positive solid tumors: LIBRETTO-001
|
Ohe, Y.
|
|
|
35 |
S3 |
p. S1322
|
artikel
|
| 181 |
O5-2 WJOG (West Japan Oncology Group) Breast Cancer Consensus Meeting 2023
|
Kimura, Y.
|
|
|
35 |
S3 |
p. S1316-S1317
|
artikel
|
| 182 |
P14-8 A case of carcinomatosis of the bone marrow from rectum surviving by remarkable response with cetuximab
|
Sanechika, Y.
|
|
|
35 |
S3 |
p. S1370
|
artikel
|
| 183 |
P91-4 A case of immune checkpoint inhibitor-associated myasthenia gravis in advanced breast cancer
|
Nio, K.
|
|
|
35 |
S3 |
p. S1394
|
artikel
|
| 184 |
P93-4 A case of lung adenocarcinoma with EGFR L858R caused by a rare 2-base deletion-insertion mutation detected by NGS
|
Fujiwara, T.
|
|
|
35 |
S3 |
p. S1395
|
artikel
|
| 185 |
P59-3 A comparison of overall survival of HCC advance stage from viral hepatitis between systemic group and palliative group
|
Phetchoo, P.
|
|
|
35 |
S3 |
p. S1384
|
artikel
|
| 186 |
P37-1 A diagnostic nomogram for pathological invasiveness in early LUAD: integration of autoantibody and radiomics features
|
Gao, Z.
|
|
|
35 |
S3 |
p. S1376-S1377
|
artikel
|
| 187 |
P91-3 A lower dose of trastuzumab deruxtecan (T-Dxd) is effective in controlling HER2-positive metastatic breast cancer
|
Hsieh, Y. Pei
|
|
|
35 |
S3 |
p. S1394
|
artikel
|
| 188 |
P54-4 Alpha-fetoprotein-secreting mucinous adenocarcinoma of the rectum: a case report
|
Maravilla, R.B.
|
|
|
35 |
S3 |
p. S1382
|
artikel
|
| 189 |
P12-7 A MSI-H mutational advanced gastric cancer case with Bulky N treated by pembrolizumab as a first-line therapy
|
Kobayashi, K.
|
|
|
35 |
S3 |
p. S1370
|
artikel
|
| 190 |
P4-3 An experience of pola-R-CHP regimen for DLBCL patients at our hospital
|
Takahata, T.
|
|
|
35 |
S3 |
p. S1365
|
artikel
|
| 191 |
P21-3 A pilot study on miRNA detection in residual of liquid-based high-risk genotype HPV samples for ovarian cancer diagnosis
|
Chu, E.S.M.
|
|
|
35 |
S3 |
p. S1373
|
artikel
|
| 192 |
P106-3 Application of cerrobend testicular shield by 3D printing and metal cutting in radiotherapy patients: a pilot study
|
Maulana, M. Iqbal
|
|
|
35 |
S3 |
p. S1400
|
artikel
|
| 193 |
P75-1 A rare case of gastrocnemius metastasis from bladder cancer with durable response to platinum-based chemotherapy
|
Elias, J. Munchar
|
|
|
35 |
S3 |
p. S1388
|
artikel
|
| 194 |
P12-3 A real world retrospective study of advanced gastric cancer patients treated with nivolumab plus chemotherapy
|
Komoda, M.
|
|
|
35 |
S3 |
p. S1370
|
artikel
|
| 195 |
P30-2 A scoping review on prevalence of anxiety and depression (AnD) in adolescent and young adult cancer (AYAO) patients
|
Teo, T.
|
|
|
35 |
S3 |
p. S1375
|
artikel
|
| 196 |
P91-5 A single-center retrospective study of 14 patients using olaparib for metastatic breast cancer
|
Ishiba, T.
|
|
|
35 |
S3 |
p. S1394-S1395
|
artikel
|
| 197 |
P105-3 Assesing the efficacy of ipilimumab as prostate cancer treatment: a systematic review
|
Victoryno, T.
|
|
|
35 |
S3 |
p. S1400
|
artikel
|
| 198 |
P11-9 Association of Charlson Comorbidity Index and safety of endoscopic resection gastric cancer patients: systematic review
|
Sutanto, R.
|
|
|
35 |
S3 |
p. S1369-S1370
|
artikel
|
| 199 |
P80-2 Awareness, knowledge, and attitude towards lung cancer among adult patients at a general hospital in Bangladesh
|
Sultana, F.
|
|
|
35 |
S3 |
p. S1389
|
artikel
|
| 200 |
P54-5 Bevacizumab with chemotherapy in colorectal cancer: a systematic review
|
Tolani, H.H.
|
|
|
35 |
S3 |
p. S1383
|
artikel
|
| 201 |
P74-1 Case of nasopharyngeal carcinoma with intracranial extension presenting as an occult primary with bilateral neck masses
|
Japzon, J.M.
|
|
|
35 |
S3 |
p. S1388
|
artikel
|
| 202 |
P16-7 Case report: a diffuse large B-cell non-Hodgkin lymphoma mixed Follicullar lymphoma in elderly with complete response
|
Sugianto, G.C.K.
|
|
|
35 |
S3 |
p. S1371
|
artikel
|
| 203 |
P46-3 Case series on stereotactic body radiation therapy in primary lung cancer & metastases: early experiences from Indonesia
|
Giselvania, A.
|
|
|
35 |
S3 |
p. S1380
|
artikel
|
| 204 |
P89-4 CCDN1 polymorphism is associated with tumor size in breast cancer patients in Bali
|
Sadeva, I.
|
|
|
35 |
S3 |
p. S1393
|
artikel
|
| 205 |
P16-6 Challenges in managing refractory classical Hodgkin lymphoma in a developing country
|
Priantono, D.
|
|
|
35 |
S3 |
p. S1371
|
artikel
|
| 206 |
P5-4 Characteristics and treatment outcomes of T-cell lymphoma in tertiary referral cancer center in Jakarta-Indonesia
|
Amelia, D.A.R.
|
|
|
35 |
S3 |
p. S1366
|
artikel
|
| 207 |
P18-4 Chinese herbal medicines in lung cancer – a double-edged sword
|
Cheng, C.
|
|
|
35 |
S3 |
p. S1372
|
artikel
|
| 208 |
P28-3 Clinical application of portable fNIRS to measure cognitive impairment after chemotherapy in a colorectal cancer patient
|
Saita, K.
|
|
|
35 |
S3 |
p. S1374-S1375
|
artikel
|
| 209 |
P99-2 Clinical characteristics of osteosarcoma in tertiary referral cancer center hospital in Jakarta, Indonesia
|
Sari, C.
|
|
|
35 |
S3 |
p. S1398
|
artikel
|
| 210 |
P100-1 Clinicopathological and molecular analysis of cancer of unknown primary with chromatin remodeling gene alterations
|
Tono, Y.
|
|
|
35 |
S3 |
p. S1398
|
artikel
|
| 211 |
P93-1 Coexistence of tuberculosis and lung cancer: a case report
|
Pham, G. Hoang
|
|
|
35 |
S3 |
p. S1395
|
artikel
|
| 212 |
P89-1 Comparative effectiveness of T-DM1 and T-DXd in the treatment of metastatic breast cancer: a systematic review of RCTs
|
Angelita, H.
|
|
|
35 |
S3 |
p. S1392
|
artikel
|
| 213 |
P113-3 Comparison between HPV test and liquid-based cytology for cervical cancer detection: a systematic review and meta-analysis
|
Sutedja, C.A.
|
|
|
35 |
S3 |
p. S1403
|
artikel
|
| 214 |
P104-3 Comprehensive genomic analysis of advanced melanoma with low to no UV radiation exposure in Asian patients
|
Lin, Y.T.
|
|
|
35 |
S3 |
p. S1399
|
artikel
|
| 215 |
P6-9 COVID-19 patients with myeloid malignancy in our hospital
|
Kin, Y.
|
|
|
35 |
S3 |
p. S1367
|
artikel
|
| 216 |
P96-8 C-reactive protein as prognostic factor in glioma: a systematic review and meta-analysis
|
Lim, Y.
|
|
|
35 |
S3 |
p. S1397
|
artikel
|
| 217 |
P50-1 ctDNA as promising biomarker to refine adjuvant treatment and prognostic value in colorectal cancer: systematic review
|
Jhoputri, C. Fricilia
|
|
|
35 |
S3 |
p. S1381
|
artikel
|
| 218 |
P29-1 Current situation and problems of cancer genome profiling in an uncertified hospital of genomic medicine
|
Muranaka, T.
|
|
|
35 |
S3 |
p. S1375
|
artikel
|
| 219 |
P48-2 Deep learning-based artificial intelligence for multiple pulmonary nodules identification: a systematic review
|
Sidharta, F.
|
|
|
35 |
S3 |
p. S1380
|
artikel
|
| 220 |
P9-1 Deep learning in detection of Epstein-Barr virus-associated gastric cancer in histology slides: systematic review
|
Sutanto, R.
|
|
|
35 |
S3 |
p. S1368
|
artikel
|
| 221 |
P109-7 Defining a group of oligometastatic nasopharyngeal carcinoma patients with improved survival outcomes
|
Kee, W.
|
|
|
35 |
S3 |
p. S1401-S1402
|
artikel
|
| 222 |
P1-8 Definitive chemoradiation with Folfox regimen in locally advanced middle-lower third esophageal cancer in Vietnam
|
Hoang, G. Ngoc
|
|
|
35 |
S3 |
p. S1364
|
artikel
|
| 223 |
P107-5 De novo adenosquamous carcinoma of the prostate: a case report
|
Domingo, C.G.
|
|
|
35 |
S3 |
p. S1401
|
artikel
|
| 224 |
P21-2 Detection of HPV from the residual of liquid-based cytology samples using multiplex digital PCR: a pilot study
|
Chu, E.S.M.
|
|
|
35 |
S3 |
p. S1373
|
artikel
|
| 225 |
P80-1 Dose-response association between alcohol consumption and kidney cancer risk according to glycemic status
|
Park, J.
|
|
|
35 |
S3 |
p. S1389
|
artikel
|
| 226 |
P88-3 Effectiveness and safety of trastuzumab emtansine in patients with breast cancer: meta-analysis of clinical trials
|
Budiputri, C.L.
|
|
|
35 |
S3 |
p. S1392
|
artikel
|
| 227 |
P98-3 Effectiveness of pembrolizumab adjuvant compared to placebo in stage 3 melanoma: a systematic review
|
Subrata, J.A.K.
|
|
|
35 |
S3 |
p. S1397
|
artikel
|
| 228 |
P94-1 Effective trastuzumab deruxtecan salvage in HER2-mutant metastatic breast cancer after pertuzumab-trastuzumab failure
|
Hsieh, Y. Pei
|
|
|
35 |
S3 |
p. S1396
|
artikel
|
| 229 |
P87-9 Effect of pembrolizumab as neoadjuvant therapy in early triple-negative breast cancer: a systematic review
|
Sunaryo, R.V.
|
|
|
35 |
S3 |
p. S1391-S1392
|
artikel
|
| 230 |
P11-6 Effects of trastuzumab therapy on overall survival in HER2-positive gastric cancer: a systematic review
|
Vania, M.
|
|
|
35 |
S3 |
p. S1369
|
artikel
|
| 231 |
P65-6 Efficacy and safety of acupuncture in breast cancer patients with taxane-induced peripheral neurotoxicity
|
Ishiki, H.
|
|
|
35 |
S3 |
p. S1386
|
artikel
|
| 232 |
P82-1 Efficacy and safety of bone management agents administered at 12 vs. 4 weeks in bone metastases: a systematic review
|
Sato, J.
|
|
|
35 |
S3 |
p. S1390
|
artikel
|
| 233 |
P42-5 Efficacy and safety of camrelizumab and carboplatin and pemetrexed in advanced nonsquamous NSCLC: A systematic review
|
Hasan, J.I.X.
|
|
|
35 |
S3 |
p. S1379
|
artikel
|
| 234 |
P37-5 Efficacy and safety of cemiplimab in non-small-cell lung cancer: systematic review and meta-analysis
|
Subroto, D.R.T.
|
|
|
35 |
S3 |
p. S1377
|
artikel
|
| 235 |
P4-2 Efficacy and safety of chimeric antigen receptor-T cells in B cell lymphoma malignacy: a systematic review meta-analysis
|
Kurniawan, A.
|
|
|
35 |
S3 |
p. S1365
|
artikel
|
| 236 |
P112-6 Efficacy and safety of dabrafenib as a potential treatment for pediatric patients with BRAF V600-mutant low-grade glioma
|
Pamula, M.J.
|
|
|
35 |
S3 |
p. S1403
|
artikel
|
| 237 |
P5-2 Efficacy and safety of extracorporeal photopheresis as immunotherapy for cutaneous T-cell lymphoma: a systematic review
|
Cheryl, A.J.
|
|
|
35 |
S3 |
p. S1366
|
artikel
|
| 238 |
P38-2 Efficacy and safety of lazertinib in the treatment of EGFR-mutated non-small cell lung cancer: a systematic review
|
Evangeline Gunawan, J.
|
|
|
35 |
S3 |
p. S1377
|
artikel
|
| 239 |
P90-6 Efficacy and safety of neratinib and capecitabine in HER2-positive metastatic breast cancer: a systematic review
|
Mokalu, E. Wilhelmina
|
|
|
35 |
S3 |
p. S1393
|
artikel
|
| 240 |
P42-3 Efficacy and safety of nivolumab and ipilimumab compared to chemotherapy in metastatic NSCLC: a systematic review
|
Yossy, P.
|
|
|
35 |
S3 |
p. S1379
|
artikel
|
| 241 |
P114-6 Efficacy and safety of pembrolizumab in patients with uterine neoplasms: a systematic review
|
Nariswari, S.A.
|
|
|
35 |
S3 |
p. S1404
|
artikel
|
| 242 |
P110-7 Efficacy and safety of pembrolizumab in recurrent or metastatic head and neck carcinoma as first-line therapy
|
Ito, K.
|
|
|
35 |
S3 |
p. S1402
|
artikel
|
| 243 |
P77-2 Efficacy and safety of remimazolam tosilate versus propofol in patients undergoing gastrointestinal endoscopy
|
Liauw, R.
|
|
|
35 |
S3 |
p. S1389
|
artikel
|
| 244 |
P45-3 Efficacy and safety of TS-ONE in advanced non-small cell lung cancer in Thailand: a multicenter retrospective study
|
Maneenil, K.
|
|
|
35 |
S3 |
p. S1379-S1380
|
artikel
|
| 245 |
P37-4 Efficacy and toxicity of pemetrexed and cisplatin in early stage non-small cell lung cancer: a systematic review of RCTs
|
Kumala, M. Gracia
|
|
|
35 |
S3 |
p. S1377
|
artikel
|
| 246 |
P7-3 Efficacy of azacitidine and venetoclax in treating acute myeloid leukemia: a systematic review
|
Gunawan, Y. Raynard
|
|
|
35 |
S3 |
p. S1367
|
artikel
|
| 247 |
P85-4 Efficacy of fulvestrant combined regimens compared to fulvestrant monotherapy in breast neoplasm: a systematic review
|
Kartono, W. Sadrakh
|
|
|
35 |
S3 |
p. S1390-S1391
|
artikel
|
| 248 |
P105-5 Efficacy of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma: a systematic review
|
Budianto, C.J.
|
|
|
35 |
S3 |
p. S1400
|
artikel
|
| 249 |
P1-7 Efficacy of nivolumab for esophageal cancer patients with PD-L1 CPS ≥1% and ≥5%: a systematic review and meta-analysis
|
Noersamsjah, A.M.
|
|
|
35 |
S3 |
p. S1364
|
artikel
|
| 250 |
P109-9 Efficacy of pembrolizumab-chemotherapy vs. cetuximab-chemotherapy in head and neck squamous cell carcinoma
|
Jeanice, T.
|
|
|
35 |
S3 |
p. S1402
|
artikel
|
| 251 |
P89-3 Efficacy of pembrolizumab in advanced TNBC: a systematic review and meta-analysis
|
Muyasarah, K.
|
|
|
35 |
S3 |
p. S1392-S1393
|
artikel
|
| 252 |
P10-4 Efficacy of pembrolizumab versus paclitaxel for gastric cancer: meta-analysis
|
Albert, N.
|
|
|
35 |
S3 |
p. S1369
|
artikel
|
| 253 |
P39-3 Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer patients: a systematic review
|
Yunita, E.
|
|
|
35 |
S3 |
p. S1377-S1378
|
artikel
|
| 254 |
P91-1 Efficacy of tamoxifen as a serm drugs in combined with other drugs for metastatic breast cancer: a systematic review
|
Huang, E.
|
|
|
35 |
S3 |
p. S1394
|
artikel
|
| 255 |
P54-7 Efficacy of various adjuvant chemotherapy in colorectal cancer
|
Gill, J.
|
|
|
35 |
S3 |
p. S1383
|
artikel
|
| 256 |
P98-1 Efficacy of vemurafenib in patients with melanoma: a systematic review
|
Harliman, R. Christopher
|
|
|
35 |
S3 |
p. S1397
|
artikel
|
| 257 |
P11-3 Efficay and safety of chemotherapy plus nivolumab for advanced gastric cancer with ascites
|
Matsumoto, T.
|
|
|
35 |
S3 |
p. S1369
|
artikel
|
| 258 |
P64-1 Efforts to improve the drug accessibility using the patient-proposed healthcare services-a company perspective
|
Hayase, N.
|
|
|
35 |
S3 |
p. S1385
|
artikel
|
| 259 |
P58-2 Epithelioid hemangioendothelioma of the liver: a case report
|
Domingo, C.G.
|
|
|
35 |
S3 |
p. S1384
|
artikel
|
| 260 |
P39-4 Evaluating the efficacy of lorlatinib versus crizotinib in ALK-positive lung cancer patients: a systematic review
|
Sito, W.W.
|
|
|
35 |
S3 |
p. S1378
|
artikel
|
| 261 |
P9-4 Experiences with trastuzumab deruxtecan in 11 cases of advanced gastric cancer
|
Yamane, H.
|
|
|
35 |
S3 |
p. S1368
|
artikel
|
| 262 |
P49-2 Feasibility and safety of exercise in rectal cancer during chemoradiation: a systematic review
|
Sucahyo, E.C.K.
|
|
|
35 |
S3 |
p. S1380-S1381
|
artikel
|
| 263 |
P76-2 Financial catastrophe in cancer patients having radiotherapy under Indonesia's health insurance scheme: midterm results
|
Putra, A. Prawira
|
|
|
35 |
S3 |
p. S1388-S1389
|
artikel
|
| 264 |
P114-5 Gemcitabine combination vs gemcitabine alone in platinum-resistant/refractory ovarian cancer: a systematic review
|
Lokanata, M. Geraldi
|
|
|
35 |
S3 |
p. S1404
|
artikel
|
| 265 |
P99-1 Incidence and mortality rate soft tissue sarcoma in Mongolia
|
Tovuu, L.
|
|
|
35 |
S3 |
p. S1397
|
artikel
|
| 266 |
P35-3 Internet-delivered cognitive behavioural therapy effect in breast cancer survivors: a systematic review
|
Colfoort, K.
|
|
|
35 |
S3 |
p. S1375-S1376
|
artikel
|
| 267 |
P50-3 Is aspirin an excellent option to prevent colorectal adenoma risk: a systematic review
|
Sutanto, R.
|
|
|
35 |
S3 |
p. S1381
|
artikel
|
| 268 |
P5-3 Ki-67 as a predictor of survival factor in diffuse large B-cell lymphoma patients at Dharmais NCC: a retrospective study
|
Syafiyah, A.H.
|
|
|
35 |
S3 |
p. S1366
|
artikel
|
| 269 |
P110-4 Low compared to high dose regiment of induction chemotherapy in nasopharingeal cancer: a systematic review meta-analysis
|
Kurniawan, A.
|
|
|
35 |
S3 |
p. S1402
|
artikel
|
| 270 |
P108-2 Machine learning application in colorectal cancer screening from histopathology whole slide images
|
Chu, E.S.M.
|
|
|
35 |
S3 |
p. S1401
|
artikel
|
| 271 |
P103-5 Malignant peritoneal mesothelioma treated with pembrolizumab & lenvatinib, cytoreductive surgery & HIPEC: a case report
|
Japzon, N.P.
|
|
|
35 |
S3 |
p. S1398-S1399
|
artikel
|
| 272 |
P57-9 Meta analysis of lenvatinib vs. sorafenib following atezolizumab + bevacizumab in advanced hepatocellular carcinoma
|
Budiman, R.A.
|
|
|
35 |
S3 |
p. S1384
|
artikel
|
| 273 |
P18-1 miRNA-224 as novel prognostic marker in cancer: a systematic review and meta-analysis
|
Kusuma, I.
|
|
|
35 |
S3 |
p. S1372
|
artikel
|
| 274 |
P76-1 Modern radiotherapy in treating subependymal giant cell astrocytoma (SEGA): a systematic review of case reports
|
Putra, A. Prawira
|
|
|
35 |
S3 |
p. S1388
|
artikel
|
| 275 |
P81-4 Nivolumab-related myositis, myocarditis and cytokine release syndrome: a case report
|
Phamnguyen, Q.
|
|
|
35 |
S3 |
p. S1390
|
artikel
|
| 276 |
P93-5 Non-small cell lung cancer with loss of CDKN2A responding to CDK4/6 inhibitor: a case report
|
Yamauchi, C.
|
|
|
35 |
S3 |
p. S1395-S1396
|
artikel
|
| 277 |
P61-5 Objective indicator for the induction of 2L chemotherapy after nab-PTX + GEM in patients with advanced pancreatic cancer
|
Iede, K.
|
|
|
35 |
S3 |
p. S1385
|
artikel
|
| 278 |
P108-3 Oncology drug regimen prediction using machine learning for knowledge graph
|
Nio, M.
|
|
|
35 |
S3 |
p. S1401
|
artikel
|
| 279 |
P90-7 Orthopaedic management for cancer treatment-induced bone loss in postmenopausal breast cancer patients
|
Tsujino, S.
|
|
|
35 |
S3 |
p. S1393-S1394
|
artikel
|
| 280 |
P56-2 Papillary thyroid carcinoma and gastrointestinal stromal tumor –metachronous tumor: a case report
|
Aguero, M.R.
|
|
|
35 |
S3 |
p. S1383
|
artikel
|
| 281 |
P85-7 PARP inhibitors and chemotherapy in breast cancer patients with BRCA-1 or BRCA-2 gene mutations: a systematic review
|
Arivia, C.
|
|
|
35 |
S3 |
p. S1391
|
artikel
|
| 282 |
P103-9 Partial response to docetaxel and gemcitabine chemotherapy in a patient with HG-ESS stage IV: a case report
|
Yamamoto, F.
|
|
|
35 |
S3 |
p. S1399
|
artikel
|
| 283 |
P69-1 Patient acceptance survey of device changes
|
Nakamura, K.
|
|
|
35 |
S3 |
p. S1387
|
artikel
|
| 284 |
P4-5 Patient characteristics and treatment patterns in patients with Mantle cell lymphoma in Japan: a real-world study
|
Rai, S.
|
|
|
35 |
S3 |
p. S1365-S1366
|
artikel
|
| 285 |
P36-3 Patterns of cancer patient presentation to the emergency department: a single institution study
|
Rajeswaran, V.
|
|
|
35 |
S3 |
p. S1376
|
artikel
|
| 286 |
P65-4 PembrolIzumab plus platinum and gemcitabine as first-line treatment of recurrent head and neck squamous cell carcinoma
|
Wan Ishak, W. Binti
|
|
|
35 |
S3 |
p. S1386
|
artikel
|
| 287 |
P10-2 Perioperative & postoperative oxaliplatin and S-1 (SOX) adjuvant chemotherapy on gastric cancer patients' D2 gastrectomy
|
Subrata, J.A.K.
|
|
|
35 |
S3 |
p. S1368
|
artikel
|
| 288 |
P17-4 Phenol stimulates tumor proliferation and metastasis through regulating β-3 adrenergic receptor
|
Lin, C. Yu
|
|
|
35 |
S3 |
p. S1371-S1372
|
artikel
|
| 289 |
P20-1 Photodynamic-controllable smart delivery of combined PARP inhibitor with natural nanoparticles for anticancer treatment
|
Onggarbek, A.
|
|
|
35 |
S3 |
p. S1372
|
artikel
|
| 290 |
P50-4 PiRNA-823 as a prognostic, non-invasive biomarker in colorectal cancer: a systematic review
|
Cendera, C. Ardalin
|
|
|
35 |
S3 |
p. S1381-S1382
|
artikel
|
| 291 |
P15-8 Polatuzumab vedotin plus bendamustine and rituximabfor elderly DLBCL patients with severe complications
|
Goto, H.
|
|
|
35 |
S3 |
p. S1370-S1371
|
artikel
|
| 292 |
P73-9 Primary ovarian small cell carcinoma of pulmonary type diagnosed with an ultrasound-guided cervical lymph node biopsy
|
Jingu, D.
|
|
|
35 |
S3 |
p. S1387-S1388
|
artikel
|
| 293 |
P58-1 Prognostic role of NLR in HCC patients underwent stereotactic body radiotherapy: a meta-analysis
|
Halim, D.A.
|
|
|
35 |
S3 |
p. S1384
|
artikel
|
| 294 |
P61-1 Prognostic value of metabolic tumor volume in patients with resectable pancreatic cancer: a meta-analysis
|
Koerniawan, H.S.
|
|
|
35 |
S3 |
p. S1385
|
artikel
|
| 295 |
P3-3 Progression-free survival and overall survival of pembrolizumab for patients with esophageal cancer: a meta-analysis
|
Santoso, K. Aurelia
|
|
|
35 |
S3 |
p. S1365
|
artikel
|
| 296 |
P113-4 Progression-free survival of niraparib in patients with platinum-sensitive recurrent ovarian cancer: meta-analysis
|
Purushotama, N.B.S.A.
|
|
|
35 |
S3 |
p. S1403
|
artikel
|
| 297 |
P27-1 Psychological readiness for salvage chemotherapy: adult patients with hematological malignancies who have first relapsed
|
Akashi, K.
|
|
|
35 |
S3 |
p. S1374
|
artikel
|
| 298 |
P66-3 Questionnaire survey on technical support for the research project on practical research for innovative cancer control
|
Sano, Y.
|
|
|
35 |
S3 |
p. S1387
|
artikel
|
| 299 |
P2-1 Real-world clinical outcomes of nivolumab as a second- or later-line therapy for esophageal squamous cell carcinoma
|
Ohsawa, M.
|
|
|
35 |
S3 |
p. S1364
|
artikel
|
| 300 |
P27-3 Report of the cancer salon at Jichi Medical University Hospital – the 9th report
|
Yamamoto, R.
|
|
|
35 |
S3 |
p. S1374
|
artikel
|
| 301 |
P96-3 Repurposing a world-approved drug to target Sp1 is a promising new approach to treating glioblastoma
|
Yang, W.
|
|
|
35 |
S3 |
p. S1396-S1397
|
artikel
|
| 302 |
P39-7 Retrospective analysis of gefitinib combined with carboplatin plus pemetrexed for NSCLC with activating EGFR mutations
|
Tsurumi, K.
|
|
|
35 |
S3 |
p. S1378
|
artikel
|
| 303 |
P90-3 Safety and efficacy of neratinib in patients with HER 2 breast cancer: a systematic review
|
Christianto, P.
|
|
|
35 |
S3 |
p. S1393
|
artikel
|
| 304 |
P7-1 Safety and efficacy of nivolumab as the initial treatment for patients with leukemia: a systematic review
|
Subroto, D.T.
|
|
|
35 |
S3 |
p. S1367
|
artikel
|
| 305 |
P105-2 Safety and efficacy of olaparib in metastatic castration-resistant prostate cancer with DNA damage repair aberrations
|
Liauw, R.
|
|
|
35 |
S3 |
p. S1399-S1400
|
artikel
|
| 306 |
P3-2 Safety and efficacy of toripalimab on esophageal cancer: a systematic review and meta-analysis
|
Subroto, D.T.
|
|
|
35 |
S3 |
p. S1364-S1365
|
artikel
|
| 307 |
P65-1 Safety and pharmacokinetics (PK) of TAR-210 in Japanese with bladder cancer and select FGFR alterations: phase 1 study
|
Nishimura, K.
|
|
|
35 |
S3 |
p. S1386
|
artikel
|
| 308 |
PS2-2 Analysis of ctDNA changes in locally advanced rectal cancer that underwent neoadjuvant treatment - GALAXY trial
|
Hamabe, A.
|
|
|
35 |
S3 |
p. S1312
|
artikel
|
| 309 |
P107-3 SBRT and IMRT in localized prostate cancer: genitourinary toxicity comparison
|
Wandana, A.
|
|
|
35 |
S3 |
p. S1400-S1401
|
artikel
|
| 310 |
PS3-3 Clinical and biomarker data from a phase 1/2 trial of ifinatamab deruxtecan (I-DXd; DS-7300) in advanced solid tumors
|
Doi, T.
|
|
|
35 |
S3 |
p. S1315
|
artikel
|
| 311 |
PS3-1 Dato-DXd vs. chemotherapy for patients with inoperable/metastatic HR+/HER2− breast cancer: TROPION-Breast01 Asian subset
|
Tsurutani, J.
|
|
|
35 |
S3 |
p. S1314
|
artikel
|
| 312 |
PS3-2 Final OS analysis from the phase 3 TROPiCS-02 study: sacituzumab govitecan in HR+/HER2− metastatic breast cancer
|
Rugo, H.S.
|
|
|
35 |
S3 |
p. S1314-S1315
|
artikel
|
| 313 |
P66-1 SKYWALKER study: feasibility of performing RWD analysis leveraging electronic medical record data in Japan
|
Seguchi, K.
|
|
|
35 |
S3 |
p. S1386-S1387
|
artikel
|
| 314 |
P103-6 Solitary extramedullary plasmacytoma of the cervix: a case report
|
Wisman, B.A.
|
|
|
35 |
S3 |
p. S1399
|
artikel
|
| 315 |
P6-7 Sorafenib maintenance post-allogeneic HCT in reducing relapse of patients with FLT3-ITD AML: a systematic review
|
Triaswhoro, G.L.
|
|
|
35 |
S3 |
p. S1367
|
artikel
|
| 316 |
PS1-3 RELAY: final overall survival with erlotinib+ramucirumab or placebo in untreated, EGFR-mutated metastatic NSCLC (mNSCLC)
|
Nakagawa, K.
|
|
|
35 |
S3 |
p. S1313
|
artikel
|
| 317 |
P93-8 Successful switch to cisplatin-based therapy in a NSCLC patient developing carboplatin-induced hypersensitivity reaction
|
Nagata, Y.
|
|
|
35 |
S3 |
p. S1396
|
artikel
|
| 318 |
P85-2 Survival analysis of HER2 receptor negative and HER2 receptor low breast cancer patients at a Philippine hospital
|
Arenos, C.C.
|
|
|
35 |
S3 |
p. S1390
|
artikel
|
| 319 |
PSY8-2 CRO approach
|
Okuda, T.
|
|
|
35 |
S3 |
p. S1286
|
artikel
|
| 320 |
PSY7-2 Current status and issues of equalization and centralization of cancer medical care
|
Wakao, F.
|
|
|
35 |
S3 |
p. S1285
|
artikel
|
| 321 |
PSY8-1 Disparities of cancer drug affordability according to countries, healthcare systems, and financial resources
|
Park, Y.
|
|
|
35 |
S3 |
p. S1285-S1286
|
artikel
|
| 322 |
PSY4-2 Gender medicine and oncology
|
Wagner, A.D.
|
|
|
35 |
S3 |
p. S1285
|
artikel
|
| 323 |
P42-2 Systematic review of pembrolizumab vs. chemotherapy in PD-L1-positive advanced NSCLC as first line of treatment
|
Atmadji, W.
|
|
|
35 |
S3 |
p. S1378-S1379
|
artikel
|
| 324 |
PSY2-3 Update of neoadjuvant/adjuvant immune checkpoint inhibitor for early breast cancer
|
Ozaki, Y.
|
|
|
35 |
S3 |
p. S1285
|
artikel
|
| 325 |
P23-4 Targeting S1P signaling pathway in triple-negative breast cancer with TP53 mutations
|
Nagahashi, M.
|
|
|
35 |
S3 |
p. S1373-S1374
|
artikel
|
| 326 |
P91-6 T-DXd for HER2-low expressing cases breast cancer at our hospital
|
Noguchi, E.
|
|
|
35 |
S3 |
p. S1395
|
artikel
|
| 327 |
P86-1 The association between tumor-infiltrating lymphocytes (TIL) and focal adhesion kinase (FAK) in breast cancer patients
|
Indrakusuma, A.
|
|
|
35 |
S3 |
p. S1391
|
artikel
|
| 328 |
P88-2 The association of XRCC1 rs25487 polymorphism with luminal and non-luminal breast cancer subtype in Bali
|
Wulandari, P.
|
|
|
35 |
S3 |
p. S1392
|
artikel
|
| 329 |
P99-3 The case report of NUT carcinoma administrated VDC-IE therapy
|
Inagaki, Y.
|
|
|
35 |
S3 |
p. S1398
|
artikel
|
| 330 |
P54-3 The effect of gut microbiome-dependent metabolic pathways on developing risk of lethal colorectal cancer
|
Tandun, A. Maria
|
|
|
35 |
S3 |
p. S1382
|
artikel
|
| 331 |
P57-8 The efficacy and safety of lenvatinib on patients with hepatocellular carcinoma: a systematic review of RCTs
|
Wibisono, M.H.
|
|
|
35 |
S3 |
p. S1383-S1384
|
artikel
|
| 332 |
P113-6 The efficacy of olaparib in BRCA-mutated ovarian cancer: a systematic review
|
Wibisono, M.G.
|
|
|
35 |
S3 |
p. S1403-S1404
|
artikel
|
| 333 |
P35-1 The impact of COVID-19 pandemic on psychological well-being of oncology healthcare providers in Malaysia
|
Zainal, N.
|
|
|
35 |
S3 |
p. S1375
|
artikel
|
| 334 |
P87-1 The role of lifestyle interventions in preventing breast cancer recurrence: a systematic review
|
Liu, C. Angelius
|
|
|
35 |
S3 |
p. S1391
|
artikel
|
| 335 |
P47-1 The safety and efficacy of atezolizumab in small cell lung cancer: a systematic review
|
Perdana, A.W.P.
|
|
|
35 |
S3 |
p. S1380
|
artikel
|
| 336 |
P41-6 The toxicity profile of durvalumab leading to interruption for stage III non-small cell lung cancer in clinical practice
|
Teshirogi, T.
|
|
|
35 |
S3 |
p. S1378
|
artikel
|
| 337 |
P16-3 Total skin electron beam therapy (TSEBT) for mycosis fungoides: the first CARE-compliant reports from Indonesia
|
Putra, A. Prawira
|
|
|
35 |
S3 |
p. S1371
|
artikel
|
| 338 |
P21-8 Ultra-sensitive tumor-informed ctDNA assay predicts survival in advanced melanoma patients treated with ICI treatment
|
Pan, H.
|
|
|
35 |
S3 |
p. S1373
|
artikel
|
| 339 |
P35-5 Unspoken challenges managing breast cancer in a schizophrenic patient: a case report
|
Elias, J. Munchar
|
|
|
35 |
S3 |
p. S1376
|
artikel
|
| 340 |
P7-4 Venetoclax and azacitidine for acute myeloid leukemia patients: a systematic review and meta-analysis
|
Noersamsjah, A.M.
|
|
|
35 |
S3 |
p. S1368
|
artikel
|
| 341 |
P51-8 Vitamin D3 and Lysiphyllum strychnifolium extract are immunomodulator in colorectal carcinoma-bearing models
|
Sukprasert, S.
|
|
|
35 |
S3 |
p. S1382
|
artikel
|
| 342 |
P50-2 White-light versus linked-color imaging for colorectal adenocarcinoma detection: systematic review and meta-analysis
|
Sutanto, R.
|
|
|
35 |
S3 |
p. S1381
|
artikel
|
| 343 |
P64-3 Why are protocol-related queries in Japan remarkably increased compared to other regions? Survey targeting CRCs and CRAs
|
Kondo, Y.
|
|
|
35 |
S3 |
p. S1385
|
artikel
|
| 344 |
SJS-2 Developing Geriatric Oncology Centers of Excellence, perspectives from a NCI Cancer Center Director
|
Chapman, A.E.
|
|
|
35 |
S3 |
p. S1278
|
artikel
|
| 345 |
SJS-1 Multidisciplinary approach to geriatric oncology
|
Chan, L.
|
|
|
35 |
S3 |
p. S1278
|
artikel
|
| 346 |
Society Pages
|
|
|
|
35 |
S3 |
p. viii-ix
|
artikel
|
| 347 |
SY12-2 Challenges for long-term survival in extended-stage small cell lung cancer
|
Nosaki, K.
|
|
|
35 |
S3 |
p. S1303
|
artikel
|
| 348 |
SY21-3 Chemotherapy for advanced cervical cancer: current challenges and future perspectives
|
Fujiwara, H.
|
|
|
35 |
S3 |
p. S1291
|
artikel
|
| 349 |
SY19-1 Clinical application of genome profiling test for hematological malignancies
|
Sanada, M.
|
|
|
35 |
S3 |
p. S1290
|
artikel
|
| 350 |
SY8-2 Communication and decision-making in cancer care
|
Fujimori, M.
|
|
|
35 |
S3 |
p. S1301
|
artikel
|
| 351 |
SY30-3 Current status and future development of second-line or later systemic treatment for advanced biliary tract cancer
|
Morizane, C.
|
|
|
35 |
S3 |
p. S1287
|
artikel
|
| 352 |
SY18-3 Current status and future perspectives of ctDNA in head and neck cancer
|
Enokida, T.
|
|
|
35 |
S3 |
p. S1292
|
artikel
|
| 353 |
SY30-5 Current status and future prospects for perioperative treatment of biliary tract cancer
|
Nakachi, K.
|
|
|
35 |
S3 |
p. S1287
|
artikel
|
| 354 |
SY8-3 Delirium in cancer patients: based on the JPOS-JASCC Clinical Practice Guidelines – second edition
|
Tanimukai, H.
|
|
|
35 |
S3 |
p. S1301
|
artikel
|
| 355 |
SY26-2 Development of ctDNA for MRD detection in breast cancer
|
Ozaki, Y.
|
|
|
35 |
S3 |
p. S1296
|
artikel
|
| 356 |
SY2-3 Development of treatments for TNBC other than immunotherapy
|
Curigliano, G.
|
|
|
35 |
S3 |
p. S1293
|
artikel
|
| 357 |
SY22-4 Embracing community: enhancing well-being with palliative care services throughout life
|
Tagami, K.
|
|
|
35 |
S3 |
p. S1294
|
artikel
|
| 358 |
SY13-1 Emerging treatment for high risk non-muscle invasive bladder cancer: from BCG to immune checkpoint inhibitors and beyond
|
Miyake, M.
|
|
|
35 |
S3 |
p. S1304
|
artikel
|
| 359 |
SY14-3 G12C KRAS mutant colorectal cancer, optimising the target
|
Price, T.J.
|
|
|
35 |
S3 |
p. S1300
|
artikel
|
| 360 |
SY9-3 iPSC-derived next-generation T cell therapy for refractory tumors
|
Ando, M.
|
|
|
35 |
S3 |
p. S1288
|
artikel
|
| 361 |
SY24-KL1 Perioperative chemotherapy for gastric and gastroesophageal junction cancer, European perspective
|
Smyth, E.C.
|
|
|
35 |
S3 |
p. S1299
|
artikel
|
| 362 |
SY13-5 Maintenance therapy in patients with metastatic urothelial carcinoma
|
Kondoh, C.
|
|
|
35 |
S3 |
p. S1304
|
artikel
|
| 363 |
SY26-4 New epigenetic technologies for ctDNA analysis
|
Shibata, T.
|
|
|
35 |
S3 |
p. S1296
|
artikel
|
| 364 |
SY5-4 New treatment strategy for intermediate-stage hepatocellular carcinoma: combination of local and systemic therapy
|
Tsuchiya, K.
|
|
|
35 |
S3 |
p. S1297
|
artikel
|
| 365 |
SY13-2 Perioperative immunotherapy for advanced urothelial carcinoma
|
Kawashima, A.
|
|
|
35 |
S3 |
p. S1304
|
artikel
|
| 366 |
SY10-4 Pharmacokinetic and dose-finding study in cancer patients with impaired renal function
|
Fujiwara, Y.
|
|
|
35 |
S3 |
p. S1289
|
artikel
|
| 367 |
SY7-4 Prognostication in patients with advanced cancer in the last months of life
|
Hiratsuka, Y.
|
|
|
35 |
S3 |
p. S1295
|
artikel
|
| 368 |
SY5-5 Real-world clinical practice data of systemic chemotherapies for unresectable hepatocellular carcinoma from Japanese multicenter study group
|
Hiraoka, A.
|
|
|
35 |
S3 |
p. S1297
|
artikel
|
| 369 |
SY7-3 That infusion is too much, isn't it? Consider the optimal infusion volume for patients with advanced cancer
|
Ikari, T.
|
|
|
35 |
S3 |
p. S1295
|
artikel
|
| 370 |
SY18-2 The current status of comprehensive genomic profile testing in head and neck cancer
|
Imamura, Y.
|
|
|
35 |
S3 |
p. S1292
|
artikel
|
| 371 |
SY8-4 The essence of the Clinical Practice Guidelines for the care of psychologically distressed bereaved families and future prospects
|
Matsuoka, H.
|
|
|
35 |
S3 |
p. S1301
|
artikel
|
| 372 |
SY27-3 The future of “telepathology” using digital innovation
|
Yoshizawa, A.
|
|
|
35 |
S3 |
p. S1298
|
artikel
|
| 373 |
SY11-2 The mechanism of gut microbiome-mediated immunity on the clinical efficacy of anti-PD-1 immunotherapy in solid tumors
|
Lin, Y.
|
|
|
35 |
S3 |
p. S1302
|
artikel
|
| 374 |
SY12-3 Treatment for oligometastatic NSCLC
|
Kenmotsu, H.
|
|
|
35 |
S3 |
p. S1303
|
artikel
|
| 375 |
SY14-1 Unveiling BRAFV600E metastatic colorectal cancer as an entity of its own
|
Tabernero, J.
|
|
|
35 |
S3 |
p. S1300
|
artikel
|
| 376 |
SY12-1 Up-to-date strategies for prolonged survival and potential cure in locally advanced non-small cell lung cancer
|
Tanaka, K.
|
|
|
35 |
S3 |
p. S1303
|
artikel
|
| 377 |
SY19-5 Utility of circulating tumor DNA-based MRD monitoring following allogeneic transplantation in adult acute lymphoblastic leukemia
|
Yokoyama, K.
|
|
|
35 |
S3 |
p. S1290
|
artikel
|
| 378 |
Table of Contents
|
|
|
|
35 |
S3 |
p. vi-vii
|
artikel
|
| 379 |
Title Page
|
|
|
|
35 |
S3 |
p. v
|
artikel
|
Tijdschrift beschrijving